Abstract 170P
Background
The aim of the present study was to perform a real-world analysis on a large sample of patients with intermediate BCLC-B patients with HCC treated with A+B vs Lenvatinib.
Methods
The study population included patients enrolled affected by intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from eastern and western populations, who received A+B or Lenvatinib as first-line treatment. Univariate and multivariate analyses were used to evaluate predictor factors for overall survivor (OS) and progression free survivor (PFS) while prognostic factors were analyzed by univariate and multivariate analysis using Cox regression model.
Results
919 BCLC-B HCC patients were enrolled in the study: 561 (61%) received Lenvatinib and 358 (39%) received A+B. The mOS for patients receiving Lenvatinib was 21,3 months compared to 15,8 months for patients receiving A+B as first-line treatment (Lenvatinib Vs A+B): HR 0,84 p =0,22. The mPFS for patients receiving Lenvatinib was 7,34 months compared to 8,68 months for patients receiving A+B as first-line treatment (Lenvatinib vs A+B): HR 1,15 p = 0,10. The multivariate analysis confirmed no different in terms of mOS and mPFS between the two treatments. Objective response rate (ORR) was 47,11 % for patients receiving Lenvatinib and 27 % for patients receiving A+B p < 0, 000001. Patients receiving Lenvatinib experienced a significantly higher incidence of hand-foot skin reaction (HFSR), hypertension, diarrhea, fatigue, decrease appetite, hypothyroidism, and other toxicity compared to patients receiving A+B. Favorable prognostic factors for OS in Lenvatinib group was platelets >100, HR 0,68 p= 0,02. No favorable prognostic factors were found for A+B group. Favorable prognostic factors for pfs in the A+B group were in those who performed at least one TACE previously HR 0.76 p=0.02, platelets <100 HR 0.62 p=0.0067, and nlr <3 HR 0.78 p=0.04.
Conclusions
Although Lenvatinib had a greater response, the study showed no statistically significant differences between Lenvatinib and A+B in terms of efficacy, in these two cohorts of BCLC-B HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract